Pharmaceuticals division sales rose 6% at constant exchange rates, offsetting a 1.9% annual revenue decline.
Roche Holding reported first-half revenue of CHF 30.36 billion, down 1.9% year-over-year, with non-GAAP earnings per share of CHF 10.85. Currency fluctuations weighed on results, though core performance improved.
Pharmaceuticals division sales reached CHF 23.6 billion, up 6% at constant exchange rates but down 1% in Swiss francs. The company had projected CHF 24.0 billion for 2025, with USD-denominated growth of 8%.
No immediate market reaction was disclosed in the release.